OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 13,964 Shares

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 13,964 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total transaction of $51,387.52. Following the transaction, the chief executive officer now directly owns 3,798,682 shares in the company, valued at $13,979,149.76. The trade was a 0.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

OmniAb Stock Up 0.3 %

Shares of NASDAQ OABI opened at $3.67 on Thursday. The stock has a market capitalization of $518.28 million, a PE ratio of -5.92 and a beta of -0.12. The firm has a fifty day moving average of $3.49 and a 200-day moving average of $3.91. OmniAb, Inc. has a 52-week low of $3.10 and a 52-week high of $6.55.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OABI. Janus Henderson Group PLC raised its holdings in shares of OmniAb by 1.1% in the 4th quarter. Janus Henderson Group PLC now owns 7,960,321 shares of the company’s stock worth $28,179,000 after purchasing an additional 88,993 shares during the period. Dimensional Fund Advisors LP raised its holdings in OmniAb by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company’s stock valued at $10,711,000 after buying an additional 142,513 shares during the period. Rice Hall James & Associates LLC lifted its position in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after buying an additional 163,038 shares in the last quarter. Geode Capital Management LLC grew its stake in OmniAb by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 2,353,442 shares of the company’s stock worth $8,333,000 after buying an additional 28,061 shares during the period. Finally, State Street Corp increased its position in shares of OmniAb by 1.7% in the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after acquiring an additional 34,654 shares in the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on OABI. Benchmark reissued a “buy” rating and set a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.